Early Stage Programs

Our early stage programs are based on novel targets which hold high therapeutic applicability across multiple indications and disease areas. We have identified and optimized hits and leads in these programs which show efficacy in proof-of-concept studies and can be further optimized for other aspects of the candidate profile.

Image Courtesy : Shutterstock

Key assets in Impetis’ early stage programs include the following

RORγt Inhibitor Program
  • Potential “First-in-Class” opportunity for targeted Autoimmune diseases with secondary positioning in a broad range of auto-immune diseases including Type 1 Diabetes, Multiple Sclerosis and Psoriasis as well as Castration Resistant Prostate Cancer
  • A new approach to target Th17 dependent disorders
  • Retinoic acid-related orphan nuclear receptor gamma (RORγt) is a hot, but “difficult-to-drug“ target
  • Early program with multiple potent and selective RORγt inhibitors identified
  • Demonstrated efficacy in multiple preclinical models
  • Two patents filed on two different chemotypes
  • Candidate nomination stage
GPR91 Antagonists
  • Potential “First-in-Class” opportunity for NASH and other targeted indications based on pathological conditions driven by cellular oxygen deficit
  • A new approach to target oxidative stress, revascularization and hepatic inflammation based on GPR91‘s role as a peripheral oxygen sensor in NASH, AMD, Retinal Revascularization and Diabetic Nephropathy
  • Early program in Lead Optimization
  • Convincing Preclinical PoC data with lead compound for NASH with Liver Fibrosis, validating the hypothesis about MoA
  • Excellent PK profile in mouse & rat
  • Global patents filed
  • > 1000 compounds synthesized towards optimized leads
  • Candidate with high potency and selectivity being nominated